Analysts Set Generation Bio Co. (NASDAQ:GBIO) Target Price at $8.88

Generation Bio Co. (NASDAQ:GBIO) has been assigned a consensus rating of “Hold” from the six ratings firms that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, two have assigned a hold rating and three have given a buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $8.8750.

Several analysts have recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Generation Bio in a research report on Wednesday, October 8th. Citigroup reiterated a “market perform” rating on shares of Generation Bio in a research note on Wednesday, December 17th. Needham & Company LLC restated a “buy” rating and issued a $15.00 price objective on shares of Generation Bio in a research report on Friday, November 7th. Wedbush set a $5.50 price objective on Generation Bio and gave the stock an “outperform” rating in a research note on Tuesday, December 16th. Finally, Jefferies Financial Group cut Generation Bio from a “buy” rating to a “hold” rating and cut their target price for the stock from $11.00 to $5.00 in a research report on Tuesday, December 16th.

Generation Bio Stock Down 0.4%

NASDAQ GBIO opened at $5.62 on Friday. Generation Bio has a 52 week low of $3.00 and a 52 week high of $10.40. The company has a market capitalization of $37.88 million, a P/E ratio of -0.60 and a beta of 2.05. The stock’s 50-day moving average price is $5.43 and its 200-day moving average price is $5.42.

Generation Bio (NASDAQ:GBIO) last released its earnings results on Wednesday, November 5th. The company reported ($0.82) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.18) by $2.36. Generation Bio had a negative net margin of 410.13% and a negative return on equity of 94.82%. The company had revenue of $1.59 million during the quarter, compared to analyst estimates of $0.66 million. Research analysts anticipate that Generation Bio will post -1.75 EPS for the current year.

Hedge Funds Weigh In On Generation Bio

Several hedge funds have recently modified their holdings of the stock. Shay Capital LLC purchased a new position in Generation Bio during the third quarter valued at $64,000. ADAR1 Capital Management LLC bought a new position in shares of Generation Bio during the 3rd quarter valued at about $136,000. AQR Capital Management LLC purchased a new position in shares of Generation Bio during the first quarter valued at about $36,000. Cantor Fitzgerald L. P. bought a new stake in shares of Generation Bio in the third quarter worth about $606,000. Finally, Marshall Wace LLP purchased a new stake in shares of Generation Bio in the second quarter worth about $37,000. Hedge funds and other institutional investors own 95.22% of the company’s stock.

Generation Bio Company Profile

Generation Bio, Inc (NASDAQ: GBIO) is a clinical-stage genetic medicine company dedicated to developing ultra-long-term non-viral gene therapies for serious, chronic diseases. Headquartered in Cambridge, Massachusetts, Generation Bio focuses on harnessing its proprietary Gene Delivery System to deliver plasmid DNA payloads via lipid nanoparticles, enabling durable expression of therapeutic proteins in target tissues without the use of viral vectors.

The company’s lead approach is centered on a modular platform designed to address monogenic disorders and other chronic conditions that require continuous protein replacement or modulation.